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Octamer-binding factor 6 (Oct-6/Pou3f1) is
induced by interferon and contributes to
dsRNA-mediated transcriptional responses
Elisabeth Hofmann1, Ursula Reichart1, Christian Gausterer1,5, Christian Guelly2, Dies Meijer3, Mathias Müller1,4,
Birgit Strobl1*
Abstract
Background: Octamer-binding factor 6 (Oct-6, Pou3f1, SCIP, Tst-1) is a transcription factor of the Pit-Oct-Unc (POU)
family. POU proteins regulate key developmental processes and have been identified from a diverse range of
species. Oct-6 expression is described to be confined to the developing brain, Schwann cells, oligodendrocyte
precursors, testes, and skin. Its function is primarily characterised in Schwann cells, where it is required for correctly
timed transition to the myelinating state. In the present study, we report that Oct-6 is an interferon (IFN)-inducible
protein and show for the first time expression in murine fibroblasts and macrophages.
Results: Oct-6 was induced by type I and type II IFN, but not by interleukin-6. Induction of Oct-6 after IFNb
treatment was mainly dependent on signal transducer and activator of transcription 1 (Stat1) and partially on
tyrosine kinase 2 (Tyk2). Chromatin immunopreciptitation experiments revealed binding of Stat1 to the Oct-6
promoter in a region around 500 bp upstream of the transcription start site, a region different from the
downstream regulatory element involved in Schwann cell-specific Oct-6 expression. Oct-6 was also induced by
dsRNA treatment and during viral infections, in both cases via autocrine/paracrine actions of IFNa/b. Using
microarray and RT-qPCR, we furthermore show that Oct-6 is involved in the regulation of transcriptional responses
to dsRNA, in particular in the gene regulation of serine/threonine protein kinase 40 (Stk40) and U7 snRNA-
associated Sm-like protein Lsm10 (Lsm10).
Conclusion: Our data show that Oct-6 expression is not as restricted as previously assumed. Induction of Oct-6 by
IFNs and viruses in at least two different cell types, and involvement of Oct-6 in gene regulation after dsRNA
treatment, suggest novel functions of Oct-6 in innate immune responses.
Backgound
Type I interferons (IFNa/b) are pleiotropic cytokines that
exhibit antiviral, antiproliferative and immunomodula-
tory effects [1,2]. IFNa/b signal through the Janus kinase
(Jak)/signal transducer and activator of transcription
(Stat) cascade [3,4]. Upon binding of IFNa/b to its cog-
nate receptor (consisting of Ifnar1 and Ifnar2) a series of
phosphorylation events exerted by the associated kinases
Jak1 and Tyk2 leads to the activation and nuclear translo-
cation of mainly Stat1/Stat2 heterodimers. Stat1/Stat2
together with IFN regulatory factor 9 (Irf9) form the
transcription factor complex IFN-stimulated gene factor
3 (ISGF3), which binds to promoters containing an inter-
feron stimulated response element (ISRE, [5]). To a lesser
extent Stat1 homodimers are activated and induce the
expression of genes containing an IFNg activated site
(GAS, [5]) in their promoter. Type II IFN (IFNg) activates
mainly Stat1 homodimers, low levels of ISGF3 [6,7] and
induces an overlapping but not identical set of genes as
type I IFNs [4,8]. Additional Stats (e.g. Stat3, Stat5) may
also be activated by both type I and type II IFNs in a
more cell type-restricted manner, but their contribution
to IFN-triggered responses is less well established [9]. In
addition to the so-called canonical Jak/Stat pathway,
other signalling cascades can be activated and impact on
gene regulation [4]. Hundreds of IFN stimulated genes
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(ISGs), many of them still poorly characterised [10,11],
mediate the complex biological responses to IFNs.
Oct-6 (Pou3f1, SCIP, Tst-1) is a member of the Pit-
Oct-Unc (POU) family of transcription factors [12,13].
These proteins are characterised by the highly conserved
structure of their DNA-binding domain, the POU-
domain, consisting of a POU-specific domain and a
POU-homeodomain. Consequently, POU-domain tran-
scription factors recognise a common motif, the octamer
consensus motif (ATGCAAAT; [12]). Members of this
family are involved in a variety of cellular processes,
ranging from house-keeping gene function (Oct-1) to
programming of embryonic stem cells (Oct-4), develop-
ment of the immune system (Oct-1 and Oct-2), of the
pituitary gland (Pit-1) or of the nervous system (Brn-1
through -4 and Oct-6). Oct-6 belongs to the POU pro-
tein class III family, whose members are mainly involved
in neuronal development [13]. Oct-6 expression is con-
sidered cell type-restricted and has so far been described
in embryonic stem cells [14,15], developing neural and
glial cells [16], cells of neonatal testes [17], squamous
epithelia [18], proliferating epidermal keratinocytes [19],
and pancreatic b-cells [20]. Oct-6 function is mainly
characterised in Schwann cells [21,22] and considerably
less is known about its role in other cell types. Oct-6 is
crucial for the terminal differentiation of myelinating
Schwann cells and is required for the expression of early
growth response protein 2 (Egr2/Krox20), another tran-
scription factor critical for Schwann cell development
[23,24]. Oct-6-deficient mice display severe defects in
peripheral nerve myelination and, in addition, die soon
after birth from a breathing insufficiency caused by
defective migration and differentiation of certain neu-
rons in the brainstem [21,22]. Mice with a Schwann
cell-specific Oct-6 knockout (i.e. deletion of the
Schwann cell-specific enhancer element, SCE) are viable
and have severe myelination defects in the peripheral
nervous system, as Schwann cells are transiently arrested
in the promyelinating stage [25]. Mice expressing Oct-6
constitutively in Schwann cells show a persistent block
in myelination [26]. These mice have normal levels of
Egr2, but the levels of myelin genes such as myelin pro-
tein zero (Mpz), myelin basic protein (Mbp), and periph-
eral myelin protein 22 (Pmp22) are significantly reduced
[26]. Thus Oct-6 exerts activating as well as repressing
functions during myelination and correctly timed, tran-
sient expression of Oct-6 is crucial for the development
of myelinating Schwann cells. Although Oct-6 is also
expressed in oligodendrocytes, Oct-6-deficient mice do
not show any myelination defects in the central nervous
system, supposedly due to functional redundancies with
other co-expressed members of the POU protein class
III family [27]. However, transgenic overexpression of
Oct-6 in oligodendrocytes causes defective myelination
and severe neurological disease, arguing for an impact
of at least de-regulated Oct-6 on central nervous system
myelination [28].
Here, we show for the first time cytokine inducibility of
Oct-6 and its expression in cell types other than those
described before. Oct-6 expression was observed in fibro-
blasts and macrophages in response to type I and type II
IFN, during viral infections, and after treatment with the
dsRNA analogue poly(I:C). We demonstrate that the
IFNb-mediated induction is Stat1-dependent and
we identify a Stat1-binding region in the Oct-6 promoter.
In addition, we compared the transcriptomes of wild type
(WT) and Oct-6-deficient macrophages and show an
involvement of Oct-6 in the transcriptional control of a
subset of poly(I:C) responsive genes.
Results
Oct-6 is induced by IFNb treatment in fibroblasts and in a
Schwann cell line
Expression profiling of Tyk2-deficient fibroblast cell lines
revealed that Oct-6 is a gene being strongly induced by
IFNb and that depends on the presence of Tyk2 for its
full expression (C. Gausterer, B. Strobl et al., unpub-
lished). Since neither IFN inducibility nor expression of
Oct-6 in fibroblasts has been described before, we con-
firmed data in primary embryonic fibroblasts (pMEF)
using RT-qPCR analysis. Oct-6 mRNA expression was
clearly induced by IFNb treatment and induction was
reduced in the absence of Tyk2 (Figure 1A). Induction of
Oct-6 was lower than observed for the known IFN target
gene C-X-C motif chemokine 10 (Cxcl10/IP-10, Figure
1B), one of the genes most strongly induced by IFNs. In
order to test if Oct-6 expression in fibroblasts is also
detectable at the protein level, we performed immunopre-
cipitation experiments. Oct-6 protein was clearly induced
by IFNb treatment (Figure 1C). In untreated cells, Oct-6
protein could not be detected, a background band
appeared at the same intensity and similar molecular
weight as in Oct-6-deficient cells. We next tested Oct-6
DNA-binding activity with EMSAs using an oligonucleo-
tide that contains an octamer consensus motif. As shown
in Figure 1D, three DNA-binding complexes were found
in IFNb treated pMEFs. The fastest migrating complex
was only observed after treatment with IFNb and was
hardly detectable in Tyk2-deficient cells. This complex
was identified as Oct-6 by supershift with a specific anti-
body (see additional file 1) and by its absence in Oct-6-/-
cells after IFNb treatment (Figure 1E). The two other
complexes were present in all samples irrespective of
genotype and treatment. The slowest migrating complex
was identified as the ubiquitously expressed Oct-1, the
other one could so far not be assigned to a specific octa-
mer-binding protein and did not supershift with Oct-1,
Oct-2 or Oct-6 specific antibodies (see additional file 1).
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Figure 1 Oct-6 mRNA and protein is induced by IFNb in primary fibroblasts (pMEFs) in a Tyk2-dependent manner. WT and Tyk2-/- (A, B)
pMEFs were treated with IFNb for 6 h or incubated with medium alone (Ctrl). (A) Oct-6 and (B) IP-10 mRNA levels were determined by RT-qPCR
using Ube2d2 as endogenous control and calculated relative to untreated WT cells. Mean values ± SD of two independent experiments are
shown. (C) WT and Oct-6-/- pMEFs were treated with IFNb for 6 h or incubated with medium alone (0 h). Oct-6 was immunoprecipitated from
whole cell extracts; panERK was used as an input control. (D) WT and Tyk2-/- pMEFs were treated with IFNb for the times indicated. Whole cell
extracts were analysed by EMSA with an octamer motif containing oligonucleotide. (E) Oct6-/-, Oct6+/- and WT pMEFs were treated with IFNb for
the times indicated. Whole cell extracts were analysed by EMSA as described in (D). (C - E) Representatives of at least two independent
experiments are shown.
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Of note, duration of Oct-6 expression in response to
IFNb appeared consistently different in cells derived from
mice with distinct genetic backgrounds (compare WT in
Figure 1D and Figure 1E).
Since Oct-6 expression and function is best charac-
terised in developing Schwann cells, we analysed
whether IFNb can induce Oct-6 expression in this cell
type. IFNb treatment of the murine Schwann cell line
SW10 resulted in a rapid and clear increase of Oct-6
and IP-10 mRNAs (Figure 2A and 2B). Oct-6 protein
was detectable by EMSA at around 3 h to 8 h after
IFNb stimulation, although levels were consistently
quite low (Figure 2C). In accordance with their imma-
ture phenotype [29], Oct-6 DNA-binding activity was
not detectable in untreated SW10 cells (Figure 2C).
Oct-6 is induced by IFNb and IFNg in macrophages
Macrophages are important cells of the immune system
and their response to IFNb is crucial in many infection
and disease models. We thus tested bone marrow-
derived macrophages (BMMs) for Oct-6 expression.
Oct-6 mRNA and DNA-binding activity were clearly
induced by IFNb in macrophages (Figure 3A and 3B).
Similar to MEFs, induction of Oct-6 DNA-binding was
detectable with EMSA from 3 h IFNb treatment
onwards (Figure 3A), and Oct-6 was not detectable in
untreated cells. Again, identity of Oct-6 was confirmed
with anti-Oct-6 supershifts and, additionally, by demon-
strating migration behaviour of overexpressed Oct-6 in
EMSAs (Figure 3A). Consistent with what has been
shown previously [30], constitutive Oct-1 and Oct-2
protein expression was observed in macrophages, as
proven by supershift with specific antibodies (Figure
3A). Notably, Oct-6 protein expression and DNA-
binding activity was considerably higher in macrophages
than in fibroblasts and SW10 cells. Since IFNg also
induces several genes that are induced by IFNa/b, we
tested whether Oct-6 is also induced by IFNg. In addi-
tion, we analysed Oct-6 expression in response to inter-
leukin-6 (IL-6), another cytokine that utilises the Jak/
Stat signalling cascade but results in distinct cellular
responses. IFNg, which mainly activates Stat1, induced
Oct-6 mRNA (Figure 3B), Oct-6 protein (Figure 3D)
and DNA-binding activity (Figure 3C) to slightly lower
levels as observed in response to IFNb. In contrast, IL-6
which mainly signals via Stat3, did not result in detect-
able Oct-6 DNA-binding activity (Figure 3C).
Oct-6 expression is dependent on Stat1 and partially
dependent on Tyk2
To determine if Oct-6 induction by IFN occurs via the
canonical Jak/Stat signalling cascade, macrophages
derived from mice deficient for specific Jak/Stat compo-
nents were analysed. As expected, Oct-6 was not upregu-
lated by IFNb in cells lacking the IFNa/b receptor
subunit Ifnar1, excluding the possibility that effects
are mediated by any other component that might be pre-
sent in the IFNb preparation (Figure 4A). As in MEFs
(Figure 1C), Oct-6 induction was partially dependent on
the presence of Tyk2 (Figure 4A). Importantly, Oct-6 was
hardly detectable in cells lacking Stat1 (Figure 4A),
although low level of Oct-6 was consistently detectable
after 24 h IFNb treatment. Thus, Oct-6 induction occurs
mainly in a Stat1-dependent manner. Stat1 induces tran-
scription of interferon regulatory factor 1 (Irf1), a tran-
scription factor that can bind to ISREs and is required
for the regulation of a subset of IFN-responsive genes
[31]. No difference in Oct-6 mRNA expression was
Figure 2 IFNb induces expression of Oct-6 in the murine Schwann cell line SW10. Cells were treated with IFNb for the times indicated or
incubated with medium alone (0 h). (A) Oct-6 and (B) IP-10 mRNA levels were determined by RT-qPCR as described in the legend to Figure 1B.
Data are depicted relative to cells incubated without IFNb from one of the experiments. Mean values ± SD of two independent experiments are
shown. (C) Whole cell extracts were analysed by EMSA as described in the legend of Figure 1 D. A representative of two independent
experiments is shown.
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found in Irf1-deficient as compared to WT cells, indicat-
ing direct involvement of Stat1 in the transcriptional acti-
vation of the Oct-6 gene (Figure 4B).
Oct-6 is induced by poly(I:C) treatment and during viral
infection via autocrine/paracrine IFNa/b signalling
We next tested whether Oct-6 is also induced by patho-
gen recognition receptor (PRR) signalling in an IFNa/b-
dependent or -independent manner [32,33]. To this end,
macrophages were either treated with poly(I:C), a syn-
thetic dsRNA analogue, or infected with Murine Cyto-
megalovirus (MCMV), both strong inducers of IFNa/b.
As shown in Figure 5A and 5B, Oct-6 DNA-binding
activity was upregulated in both scenarios. In order to
determine whether Oct-6 is induced directly by PRR sig-
nalling, e.g. via NFB or Irf3 transcription factor activa-
tion [32,33], we analysed Ifnar1-, IFNb-, Tyk2- and
Stat1-deficient macrophages in response to poly(I:C).
Oct-6 expression was completely dependent on Ifnar1,
demonstrating that Oct-6 expression after poly(I:C)
treatment is mediated by autocrine/paracrine actions of
IFNa/b (Figure 5C). Thus, in contrast to several other
ISGs (e.g. IP-10), Oct-6 induction is strictly dependent
on the presence of functional IFNa/b signalling. Unlike
the residual Oct-6 induction observed after treatment
with high amounts of exogenous IFNb (Figure 4A),
Oct-6 was not detectable in poly(I:C) treated Stat1-/-
cells (Figure 5C). Similarly, Tyk2 dependence was much
more pronounced under these conditions than after
treatment with high dose of exogenous IFNb. Delayed
induction was observed in cells deficient for IFNb
(Figure 5C), which is consistent with the prominent role
of IFNb in the IFNa/b amplification loop mainly
described in the context of viral infections [34]. Similar
results with respect to the requirement of the above
analysed signalling molecules were obtained after
MCMV infections (see additional file 2).
Stat1 binds to the Oct-6 promoter
We next analysed the Oct-6 promoter for potential Stat1-
binding sites (ISRE and GAS, respectively). Based on the
assumption that conservation argues for functionality of
consensus motifs, we analysed mouse, rat and human
aligned sequences upstream of the respective transcription
Figure 3 Oct-6 is induced by IFNb and IFNg in macrophages. WT BMMs were treated with IFNb, IFNg or IL-6 for the times indicated. (A, C)
Whole cell extracts were analysed by EMSA as described in the legend of Figure 1 D. (A) DNA-binding complexes were identified by supershift
of WT_8 h lysates with the respective antibodies (+AB), and by Oct-6 overexpression (ox) in a MEF cell line. (B) Oct-6 mRNA levels were
determined by RT-qPCR as described in the legend of Figure 1A. Mean values ± SD of two experiments are shown. (D) Oct-6 was
immunoprecipitated from whole cell extracts, panERK was used as an input control. (A, C, D) Representatives of at least two independent
experiments are shown.
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start sites. Within a homologous sequence part of Oct-6,
one GAS (-477 to -468) and one ISRE (-412 to -409) was
predicted by TFBS analysis using “Patch”, a publicly avail-
able program scanning input sequences for potential
TFBSs based on the Transfac database. Another GAS
(-402 to -392) located in close proximity to the predicted
ISRE was found by checking the sequences next to the
predicted sites manually. The GAS elements (Figure 6A)
show only one mismatch each compared to the consensus
sequence (TTC(N)2-4GAA, [5]). The predicted ISRE (-412
to -409) seems rather imperfect when compared to the
published consensus motif (GATTTC(N)2TTTCNY, [5]),
but is identical to the Transfac annotated ISGF3 motif
(GGAAA). To explore the possibility of Stat1-binding to
this region, chromatin immunoprecipitation (ChIP)
experiments were performed. In accordance with the
mRNA induction, increased Stat1-binding to the Oct-6
promoter was observed in response to both IFNb
and IFNg. Stat1-binding was observed with two different
PCR reactions, encompassing the regions -481 to -387 or
-481 to -243, respectively (Figure 6B, see Figure 6A for
positions of primers used). As a control, Stat1-binding to a
Figure 4 Oct-6 induction by IFNb depends on Stat1 and partially on Tyk2. (A) WT, Stat1-/- , Tyk2-/- and Ifnar1-/- BMMs were treated with
IFNb for the times indicated. Whole cell extracts were analysed by EMSA as described in the legend to Figure 1 D. A representative of at least
two independent experiments per genotype is shown. (B) WT and Irf1-/- BMMs were treated with IFNb for the times indicated and Oct-6 mRNA
expression was determined by RT-qPCR as described in the legend to Figure 1A. Mean values ± SD of two independent experiments are shown.
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well-characterised binding region in the Irf1 promoter was
performed and showed the expected pattern (Figure 6B)
[35]. Thus, Stat1 directly binds to the Oct-6 promoter
upstream of the transcription start site, most likely at the
predicted GAS and/or ISRE site(s) in the region from posi-
tion -481 to -387.
IFNb and poly(I:C) induced Oct-6 localises to the nucleus
Oct-6 contains a nuclear localisation and a nuclear
export signal, both located in the POU homeodomain
[36,37]. Although so far no post-translational modifica-
tions that direct Oct-6 to the nucleus have been identi-
fied, it has been hypothesised that its transcriptional
activity can be controlled by regulating its subcellular
localisation [36]. We therefore tested Oct-6 localisation
after IFNb and poly(I:C) treatment using immunofluor-
escence analysis. As expected, Oct-6 was not detected in
untreated cells (Figure 7 top panel). In response to IFNb
and poly(I:C), Oct-6 staining was exclusively found in
the nuclei (Figure 7). Hence, both IFNb and poly(I:C)
are sufficient to induce Oct-6 expression and nuclear
localisation in macrophages.
Absence of Oct-6 in marcrophages does not influence the
expression of Egr2, Pmp22 and IFNab mRNAs
In order to investigate the biological function of Oct-6,
we firstly analysed mRNA expression of potential target
genes in the presence or absence of Oct-6. Since Oct-
6-/- mice die soon after birth, foetal livers were used to
isolate Oct-6-/- and WT macrophages, respectively.
Similar to MEFs and BMMs, Oct-6 expression was not
detectable by immunoprecipitation in untreated foetal
liver-derived macrophages (FLMs), whereas it was
clearly expressed after poly(I:C) treatment (Figure 8A).
Inducibility of Oct-6 by poly(I:C) was similar to that
observed in BMMs as analysed by EMSA (see additional
file 3). Among the known target genes in Schwann cells,
we analysed expression of Egr2 and peripheral myelin
Figure 5 Oct-6 is induced by poly(I:C) and during MCMV infections via autocrine/paracrine actions of IFNa/b. (A, B) WT BMMs or (C)
BMMs derived from mice of the indicated genotype were (A, C) treated with poly(I:C) or (B) infected with MCMV (MOI = 1) for the times
indicated. Whole cell extracts were analysed by EMSA as described in the legend to Figure 1 D. Representatives of (A, B) three independent
experiments and (C) at least two independent experiments per genotype are shown.
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protein 22 (Pmp22) in response to poly(I:C). As shown
in Figure 8B and 8C, poly(I:C) treatment resulted in a
modest but Oct-6-independent down-regulation of both
mRNAs. Octamer consensus motifs and Oct-1 have
been implicated in negative regulation of IFNa and
IFNb gene expression [38]. Furthermore, transient trans-
fection of Oct-6 resulted in a strong upregulation of type
I IFN mRNAs (see additional file 4). However, we did
not observe any difference in the poly(I:C)-induced
expression of IFNb or IFNas (all subtypes, panIFNa)
between Oct6-/- and WT macrophages (Figure 8D and
8E). Similarly, no Oct-6-specific effects on the expres-
sion of type I IFNs were found in response DNA trans-
fection in fibroblasts (see additional file 5).
Octamer proteins can influence viral replication [12]
and the high induction of Oct-6 that we observed after
Figure 6 Stat1 binds to a conserved region in the Oct-6
promoter containing predicted GAS and ISRE sites. (A)
Alignment of the selected conserved region upstream of the Oct-6
transcription start site (base counts correlate to the murine
sequence). Potential GAS (black, bold) and ISRE (grey, bold) motifs
are indicated. Position of primers used for the PCR reaction of the
ChIP analysis are indicated by arrows. For the two PCRs, short (S)
and long (L), the same forward primer was used, the reverse primer
for the long PCR (not shown) is located 150 bp further downstream.
(B) WT BMMs were treated with IFNb (500 U/ml), IFNg (200 U/ml) or
were left untreated (Ctrl) for 1 h and 3 h. ChIP for Stat1 (a-Stat1 AB;
nonspecific rabbit serum: Ctrl AB) was performed, followed by the
two different PCRs for the Oct-6 promoter (Oct-6_S and Oct-6_L),
and a PCR for the Irf1 promoter (Irf1) as a control. Representatives of
two independent experiments are shown. Figure 7 Oct-6 localises to the nucleus in response to IFNb or
poly (I:C). WT BMMs were grown on glass slides, treated with IFNb
(middle panels) or poly(I:C) (lowest panels) for 6 h or left untreated
(upper panels). Oct-6 was detected by indirect immunofluorescence
(right panels), nuclei were stained with DAPI (left panels).
Representatives of two independent experiments are shown.
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MCMV infection in macrophages, prompted us to ana-
lyse MCMV replication in the presence or absence of
Oct-6. WT and Oct-6-deficient macrophages were
infected with MCMV and virus titer was measured over
time. No difference in viral yield was observed after
infection with a multiplicity of infection (MOI) of 1
(Figure 8F) or a MOI of 0.1 (see additional file 6).
Oct-6 contributes to the regulation of a subset of genes
in response to poly(I:C) in macrophages
In order to identify target genes of Oct-6 in the context
of innate immune responses, WT and Oct-6-/- FLMs
were treated with poly(I:C) for 8 h and transcriptional
responses were monitored using microarray analysis. A
subset of genes (n = 200) displayed a significant, at least
two-fold difference between WT and Oct-6-/- macro-
phages after poly(I:C) treatment (p <0.05). About 60% of
the genes were reduced, the rest enhanced in the
absence of Oct-6, arguing for activating as well as
repressing functions of Oct-6. Of the differentially
expressed genes, 158 could be annotated, remaining
probe sequences correlate to RIKEN cDNAs, or cDNAs
of unknown function. About half of the differentially
expressed genes (n = 96) could be grouped into classes/
pathways using functional annotation and clustering (see
additional file 7; see additional file 8 for the complete
list of differentially expressed genes). The largest group
was “Regulation of transcription” containing 15 genes,
most of them down-regulated in the absence of Oct-6,
such as Ctnnd2, Rcor3 and a number of zinc finger pro-
teins. A related category “RNA splicing” contained 3
genes, Sfrs14, Lsm10 and Sf3a1, all of which showed
reduced expression in the absence of Oct-6. Another
category “Ubiquitin cycle” contained 6 genes, half of
which were up-, half down-regulated. However, analyses
for pathway enrichment did not yield any significant
results, most likely because the number of differentially
regulated genes was too low compared to the vast
amount of GO-categories. Nevertheless, the data clearly
show that Oct-6 is involved in the regulation of tran-
scriptional responses to poly(I:C). As expected, in WT
cells poly(I:C) treatment had a major effect on the tran-
scriptome with around 3500 genes (out of 12220 genes
included in the analysis) significantly regulated (p <0.05,
Figure 8 Absence of Oct-6 in macrophages does not influence poly(I:C) induced IFNb and IFNa mRNA expression and has no impact
on MCMV replication. (A - E) WT and Oct-6-/- FLMs were treated with poly(I:C) or incubated with medium alone (0 h) for the times indicated.
(A) Oct-6 was immunoprecipitated from whole cell extracts; panERK was used as an input control. (B - E) Expression levels were determined by
RT-qPCR for (B) Egr2, (C) Pmp22, (D) IFNb, and (E) panIFNa (all subtypes) using Ube2d2 as endogenous control. (B, C, D) Data are depicted relative
to the WT 0 h control. (E) panIFNa mRNA could not be detected reliably in untreated cells (n.d.) and thus data normalised to the endogenous
control only are depicted (not additionally calibrated to untreated cells). (B - E) Mean values ± SD of three independent experiments are shown.
(F) WT and Oct-6-/- FLMs were infected with MCMV (MOI = 1) for 90 min, washed with PBS and fresh medium was added. Supernatants were
collected 0, 1, 3 and 6 days (d) after infection and virus titers were determined in a plaque forming assays using Stat1-/- MEFs. Mean values ± SD
of two independent experiments (each with FLMs from two embryos per genotype) are shown.
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minimal fold-change of 2). According to Gene Ontology
(GO) annotation (GeneSpring Expression Analysis 7.3.1
tool, Agilent Technologies), genes involved in immune
responses and cell death were significantly enriched in
the set of genes up-regulated in response to poly(I:C)
treatment (see additional file 9, sheet 1: Gene Ontology
categories up-regulated by poly(I:C) treatment in WT
cells). In the set of genes down-regulated in response to
poly(I:C) treatment, genes involved in metabolism and
cell cycle progression were significantly enriched (see
additional file 9, sheet 2: GO categories down-regulated
by poly(I:C) treatment in WT cells).
Oct-6 regulates the expression of Stk40 and Lsm10 in
response to poly(I:C)
In order to confirm the role of Oct-6 in the transcrip-
tional regulation of poly(I:C) responses, we validated
expression patterns of serine/threonine kinase 40
(Stk40) and U7 snRNP-specific Sm-like protein LSM10
(Lsm10) with RT-qPCR. Both genes showed around
two-fold reduced expression levels in the absence of
Oct-6 in the microarray experiment (p <0.01, see addi-
tional file 7). As shown in Figure 9A, Stk40 was induced
about seven-fold in WT cells after poly(I:C) treatment,
whereas the induction was only three-fold in Oct-6-/-
macrophages. Lsm10 was not significantly influenced by
poly(I:C) treatment in WT cells, but its expression was
reduced by two-fold in the absence of Oct-6 (Figure
9B). For both genes, differences in expression between
WT and Oct-6-/- macrophages after poly(I:C) treatment
were again highly significant (p <0.01).
Discussion
In this study we report for the first time expression of Oct-
6 in fibroblasts and macrophages. We show that Oct-6 is
induced by IFNb and IFNg, but not by IL-6. Expression of
Oct-6 in response to IFNb occurs mainly via the canonical
Jak/Stat signalling cascade and is dependent on the pre-
sence of Stat1 and to a lesser extent on Tyk2. Notably, we
observed delayed and low levels of Oct-6 induction in the
absence of Stat1 in response to high dose of exogenous
IFNb, suggesting that additional IFN activated factors can
mediate Oct-6 induction. Oct-6 is also expressed during
viral infection and after treatment with the synthetic
dsRNA analogue poly(I:C), in both cases mediated
by autocrine/paracrine IFNa/b signalling. Using ChIP
technology, we show that Stat1 directly binds to the Oct-6
promoter at around 387 to 481 bp upstream of the tran-
scription start site, a region containing three conserved
Stat1 consensus binding sites (i.e. two GAS sites and one
imperfect ISRE). The presence of GAS and ISRE in the
Oct-6 promoter is consistent with the responsiveness to
IFNg and IFNb, a feature that is shared with several other
IFN responsive genes. In contrast to the upstream Stat1-
binding region defined herein, an enhancer element
around 12 kb downstream of the Oct-6 gene mediates
Oct-6 expresssion during Schwann cell development. Dele-
tion of this enhancer element completely abolishes Oct-6
expression in Schwann cells without affecting its expres-
sion in other cell types [25,39]. Schwann cell-axonal con-
tact induces Oct-6 expression by possibly multiple
pathways [40], but transcription factors and co-activators
involved are still poorly characterised. NFB is required
but not sufficient for Oct-6 expression [41] and it is at pre-
sent unknown how the different signals input on the
Oct-6 enhancer element. Thus, the mechanism of gene
induction is clearly different for IFN- and Schwann
Figure 9 Expression levels of Stk40 and Lsm10 after poly(I:C)
treatment are reduced in the absence of Oct-6. WT and Oct-6-/-
FLMs were treated with poly(I:C) for 8 h or incubated with medium
alone (0 h). Expression levels of (A) Stk40 and (B) Lsm10 were
determined by RT-qPCR using Ube2d2 as endogenous control. Data
are depicted relative to untreated WT cells. Mean values ± SD of six
experiments are shown.
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cell-axonal contact-induced Oct-6 expression and involves
distinct regulatory regions. Potential cross-influence and
regulation in other cell types remain to be investigated.
Except for the ubiquitous Oct-1, expression of all
POU domain proteins is regulated in a developmental
and/or cell differentiation-dependent manner, with some
members being lineage-specifying factors [12,42,43].
Inducibility of Oct-6 in the context of innate immune
responses adds a new facet to POU domain protein biol-
ogy and raises the question if Oct-6 is unique in this
regard or if other members display similar as yet unrec-
ognised modes of regulation.
Using WT and Oct6-deficient foetal liver-derived
macrophages, we demonstrate that IFNb and poly(I:C)
treatment is sufficient to induce Oct-6 expression and
nuclear localisation. We could demonstrate a functional
role of Oct-6 in poly(I:C) induced transcriptional
responses using microarray analysis of WT compared to
Oct-6-deficient cells. 200 genes were at least two-fold
differentially expressed between WT and Oct-6-deficient
cells after poly(I:C) treatment. Genes affected by the
absence of Oct-6 were diverse with respect to functional
annotation and no specific pathway appeared as Oct-6
regulated. Using RT-qPCR we confirmed Oct-6-depen-
dent gene regulation for Lsm10 and Stk40. Interestingly,
the effect of Oct-6 on gene expression was different for
these two genes. In the case of Stk40, Oct-6 was needed
for efficient upregulation, whereas it was required for
the maintenance of Lsm10 expression after poly(I:C)
treatment. The function of Stk40, also known as SINK
homologous serine/threonine kinase (SHIK) and Lyk4, is
poorly characterised. Very recently, Stk40 has been iden-
tified as Oct-4 target gene that is required for extraem-
bryonic endoderm differentiation [44]. On the other
hand, overexpressed Stk40 was shown to inhibits TNF-
induced NFB- and p53-mediated transcription [45].
Lsm10 is a component of the U7 small nuclear ribonu-
cleoprotein (snRNP) complex, which is involved in the
formation of the 3’ end processing of canonical histone
mRNAs [46,47]. Against this background, it can be
speculated that Oct-6 influences chromatin remodelling
and cell cycle progression. More detailed gene expres-
sion analyses, in particular considering kinetic aspects,
will certainly be required in order to fully characterise
the role of Oct-6 in innate immune responses. It will
also be of major interest to determine the role of Oct-6
in innate immunity in vivo. However, since Oct-6 defi-
cient animals die soon after birth [21,22] these studies
will have to await the availability of conditional knock-
out mice.
Interestingly, absence of Oct-6 in macrophages did not
affect the expression of Egr2 and Pmp22, genes that are
regulated by Oct-6 in Schwann cells [23,48]. Thus, tar-
get genes of Oct-6 differ between cell types and/or
stimuli. Dependent on specific DNA elements and the
presence of distinct co-activators, POU proteins can
assume different conformations [49]. With respect to
co-activators, the SRY box protein Sox10 cooperates
with Oct-6 in Schwann cells and glial cells [23,50,51]. It
is reasonable to assume that distinct transcriptional co-
activators are present or activated in macrophages,
fibroblasts and Schwann cells and that these account for
the differences in target gene expression.
It seems worth considering our results also in the con-
text of neuropathologies. We demonstrate that Oct-6 is
induced by IFNb in the murine Schwann cell line SW10.
Oct-6 protein expression was very low in this cell line, but
the potency of IFNs to induce Oct-6 might be interesting
enough to prompt studies on primary Schwann cells and
in vivo. In particular in the context of inflammatory and
infection-induced neuropathologies, where IFNs are pro-
duced and Schwann cells de-differentiate and develop
again to a myelinating phenotype. We hypothesise that
IFN application or stimulation by e.g. viral infection can
influence peripheral and possibly central nervous system
myelination by triggering Oct-6 expression.
Conclusions
We identify Oct-6 as an ISG and inducible protein in
cell types where it has not been reported yet. In addition
to the known Oct-6 function mainly in developmental
processes, our report places Oct-6 as a transcriptional
(co-) activator in the innate immune response reper-
toire. Furthermore, our results provide new insights into
Oct-6 gene regulation with a potential impact on the
control of nerve myelination.
Methods
Mice and cells
Mice deficient for Ifnar1 [52], Tyk2 [53], Stat1 [54], Irf1
[55] and IFNb [56] were crossed for at least ten genera-
tions onto C57BL/6 background. Wild type (WT) mice
(C57BL/6) were purchased from Charles River Labora-
tories. Mice were housed under specific pathogen-free
conditions according to FELASA guidelines, except for
Oct-6+/- mice which were housed conventionally. Oct-6+/-
mice were of mixed background [21], Oct-6+/+ littermates
were used as WT controls. All animal experiments were
discussed and approved by the institutional ethics commit-
tee and the Austrian laws (GZ 68.205/0204-C/GT/2007
and GZ 68.205/0233-II/10b/2009). Bone marrow-derived
macrophages (BMMs) were grown in the presence of
L929 conditioned medium as described [57] and used for
experiments on day 7 after isolation. Foetal liver-derived
macrophages (FLMs) were isolated/grown by culturing
foetal liver cell suspensions (day 13.5-14.5 post concep-
tion) under the same conditions as BMMs and were used
for experiments on day 6 after isolation. Primary murine
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embryonic fibroblasts (pMEFs) were isolated and grown
from individual embryos at day 13.5-14.5 post conceptio-
nem according to standard procedures [58]. MEF cell lines
were grown as described [59]. SW10 cells were from
ATCC (Cat. No. CRL-2766; [29]) and propagated as
recommended.
Reagents, treatments and infections
Cells were treated for the indicated time points with
IFNb, IFNg or IL-6 (all purchased from Calbiochem), or
with polyinosinic-polycytidylic acid (poly(I:C), GE Health-
care). IL-6 was used at a concentration of 125 ng/ml,
poly(I:C) at 50 μg/ml, IFNb and IFNg at 1000 U/ml (if
not stated otherwise). Infections with Murine Cytomega-
lovirus (MCMV) and plaque assays were done as
described previously [59].
Whole cell extracts and immunoprecipitations (IP)
Cells were lysed in 50 mM Tris.HCl pH8, 150 mM
NaCl, 0.5% Nonidet P-40, 10% glycerol, 2 mM DTT, 0.1
mM EDTA, 0.2 mM Na3VO4, 25 mM NaF, 1 μg/ml
aprotinin, 1 μg/ml leupeptin and 1 mM PMSF. Cell deb-
ris was removed by centrifugation. 1 mg whole cell
extract/ml was incubated overnight with 2 μg anti-Oct-6
antibody (C-20, Santa Cruz) and purified with protein-G
PLUS agarose (Santa Cruz). Precipitates were separated
on 8% SDS polyacrylamide gels. Proteins were blotted
onto nitrocellulose membranes (GE Healthcare), detec-
tion was performed with a previously described rabbit
polyclonal anti-Oct-6 antibody [60]. As an input control
for IPs, whole cell extracts were analysed for panERK
(pan-extracellular signal regulated kinases) expression.
panERK antibody was from BD Transduction Labora-
tories. Anti-rabbit- and anti-mouse-IgG horse-raddish
peroxidase-conjugated secondary antibodies and the
ECL™-detection system were from GE Healthcare.
Electrophoretic mobility shift assays (EMSAs)
EMSAs were done as described previously [61] using
15 μg whole cell extract and an octamer consensus
motif containing oligonucleotide [62]. For supershifts,
cell extracts were incubated with 1 μl of the respective
antibody prior to the binding reaction: anti-Oct-6
(C-20), anti-Oct-1 (12F11), and anti-Oct-2 (C-20) (all
Santa Cruz).
Immunofluorescence
Cells were grown and stimulated on glass slides, and
fixed with 4% formaldehyde for 15 min (Histofix, Roth).
Formaldehyde was quenched by glycine (100 mM, 15
min), cells were permeabilised by methanol treatment
(-20°C, 5 min). Nonspecific binding was blocked with
1% BSA in PBS for 1 hour. Oct-6 was detected by incu-
bating the slides with anti-Oct-6 antibody (C-20, Santa
Cruz; 4 μg/ml in blocking solution; 4°C overnight) and a
fluorescently labelled a-goat IgG secondary antibody
(Alexa-Fluor™ 488; 1:200 in PBS; 1 hour at room
temperature). Goat IgG (Invitrogen) was used as
isotype control. Nuclei were counterstained with DAPI
(100 ng/ml).
Alignment of Oct-6 upstream sequences and transcription
factor binding site (TFBS) prediction
For the alignments, mouse, rat and human sequences from
+1 to -5 kb were used (Blast 2 sequences: http://blast.ncbi.
nlm.nih.gov/bl2seq/wblast2.cgi; March 2008). Mouse
sequence accession number NC_000070.5 (M.m. C57BL/6,
chromosome 4, reference assembly; base 124334896 = +1
on the +strand). Human sequence accession number
NC_000001_10 (H.s. chromosome 1, GRCh37 primary
reference assembly; base 38512450 = +1 on the -strand).
Rat sequence accession number NC_005104.2 (R.n., chro-
mosome 5, reference assembly; base 143981547 = +1 on
the +strand). Homologous sequence parts, i.e. -4367 to
-4500, -1598 to -3233, and -161 to -637 (base counts corre-
late to the murine sequence), were submitted to TFBS ana-
lysis analysed using “Patch” (http://www.gene-regulation.
com/pub/programs.html; August 2008), which scans input
sequences for potential TFBSs based on the Transfac data-
base. A number of Stat1- and ISGF3-binding sites were
predicted for each sequence part. We decided to concen-
trate on the homologous sequence part nearest to the tran-
scription start site (-161 to -637) of Oct-6, based on a
report showing that the regions -500 bp upstream of the
transcription start site of IFN-inducible genes are enriched
in predicted binding sites for Stat1 and ISGF3 [63].
Chromatin immunoprecipitation (ChIP)
ChIP for Stat1 was performed as described [35] with minor
modifications. Sonication (Sonopuls HD70, MS72 sono-
trode; Bandelin) was performed at 50% power and 90%
duty cycle for 10 times 15 sec with 1 min break between
the pulses. Equal amounts of lysate were used for Stat1 IP
(4 μl Stat1-C antibody/500 μl lysate; a kind gift from Pavel
Kovarik, MFPL, University of Vienna; [64]) and a control
reaction using nonspecific rabbit serum (Sigma). DNA was
isolated following a phenol:chloroform extraction protocol
and subjected to PCR analysis. PCRs were run in a final
volume of 25 μl containing 300 nM primer, 2 mM MgCl2,
200 μM dNTPs (Fermentas), 1× Biotaq buffer, 2 U Biotaq
DNA polymerase (Agrobiogen) under following cycling
conditions: 5 min at 95°C for initial denaturation, followed
by 35 cycles of 95°C for 30 sec and 61°C for 1 min. PCRs
were done from all samples of the anti-Stat1 IP, the control
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IP (nonspecific rabbit serum) and from an aliquot of the
initial sample input prior to the IP (input DNA). Following
primers were used: ChIP_Oct6-F: GTCTCTGCTCG
GAACCCGA, ChIP_Oct6_S-R: CCCACGTTCCACA
CAAGCT, ChIP_Oct6_L-R: GCCCGCGTACACATT-
CAC; ChIP_Irf1-F: GCACAGCTGCCTTGTACTTCC,
ChIP_Irf1-R: TCGGCCTCATCATTTCGG.
RNA isolation and reverse transcription (RT)
Total RNA was isolated following the TRIZOL (Invitro-
gen) protocol. Prior to cDNA synthesis, RNA was trea-
ted with 1 U/μg RNA RQ1 DNase I (Promega) in order
to digest contaminating genomic DNA. cDNA was pre-
pared from 1 μg total RNA per 20 μl reaction using the
iScript First Strand cDNA synthesis kit (BioRad), includ-
ing controls for DNA contamination (reactions without
addition of reverse transcriptase).
Real-time quantitative PCR (qPCR) analysis of gene
expression
Target gene expression was assessed by qPCR with ubi-
quitin-conjugating enzyme E2D2 (Ube2d2) as endogen-
ous control gene. Assays for IFNb and Ube2d2 were
described previously [59]. Taqman® probes labelled with
6-carboxyfluorescein (FAM) at the 5’end, and a black-
hole-quencher (BHQ1) at the 3’end were used. Eva-
Green (Biotium) assays were used for the quantification
of Oct-6, Egr2, Pmp22, Lsm10, and Stk40. Following pri-
mers were used (5’ to 3’): panIFNa:fwd-CCACAGGAT-
CACTGTGT(A/T)CCTGAGA, rev-CTGATCACCTC
CCAGGCACAG, probe-AG+AA+GAA+A+C+AC+AG
+CC (locked nuclear acids (LNAs) are indicated by a
“+” in front of the respective base; [65]);
Oct-6: fwd-AGGTCCTGTTGGAGATGATATGTT,
rev-TTGGGAAATGAATTGTCAAGAAA;
Egr2: fwd-GGTGACCATCTTCCCCAATG, rev-
TTGATCATGCCATCTCCCG;
Pmp22: fwd-CCGGTTTTACATCACTGGATTCT,
rev-TGTAGATGGCCGCTGCACT;
Lsm10: fwd-CCTCCAAAAGGCCATGAGACT, rev-
CGGGAGTTGGCTCAGAACAC;
Stk40: fwd-CTCTCAGTGCCATCATTGCATC, rev-
CACCTTTGCCTCCTGGGA.
Taqman qPCR assays were run in a final volume of 25
μl containing 300 nM primer (Invitrogen), 100 nM
probe (Sigma or Metabion), 200 μM dNTPs (Fermen-
tas), 4 mM MgCl2, 1× HotFire buffer B, and 1U HotFire
DNA polymerase (all Solis BioDyne). The conditions
were the same for the EvaGreen assays, except for the
use of 0.2× EvaGreen dye instead of the probe in the
presence of only 2.5 mM MgCl2. All qPCRs were run
on a Mastercycler® ep Realplex (Eppendorf) applying
following cycling conditions: 15 min at 95°C for initial
denaturation, then 40 to 45 cycles of 95°C for 20 sec
and 60°C for 1 min. For EvaGreen assays, the PCR was
followed by a melting curve analysis in order to confirm
assay specificity. Data were analysed using the Realplex
software (Eppendorf) and relative target gene expression
levels (i.e. n-fold expression levels) were calculated fol-
lowing the standard curve method [66,67].
Statistical analysis of RT-qPCR data. RT-qPCR gene
expression data were investigated for differences among
genotypes and time after challenge. Univariate regres-
sion was calculated with the log of the transformed tar-
get to endogenous control gene expression ratio as
dependent variable. Linear contrasts were encoded such
that for each time point Oct6-/- were compared to WT
cells. Differences among experiments were controlled
for. Data were analysed with SPSS 17.0 for Mac OS-X.
Microarray analysis
WT and Oct-6-/- FLMs were treated with 50 μg/ml poly
(I:C) for 8 hours in three independent experiments. RNA
integrity was assessed by capillary electrophoresis using a
Bioanalyser2100 (Agilent Technologies), and photometric
analysis (OD260 nm/280 nm ration of ~2.1 for all sam-
ples). RNA integrity numbers (RIN) ranged between 9.2
and 9.4 indicating high quality of RNA samples. ABI1700
Mouse Genome Survey Microarrays (Applied Biosystems)
in combination with the RT direct labelling kit (Applied
Biosystems) were used according to the manufacturer’s
recommendations to generate gene expression profiles.
20 μg of input total RNA was used for direct labelling and
microarray hybridisation. Data transformation and nor-
malisation: expression values less than 10 were set to 10.
Data were normalised to the 50th percentile (intra-array
normalisation) and each gene was normalised to the med-
ian expression (inter-array normalisation). Data were pre-
filtered based on the signal to noise ratio (cut-off level:
signal above noise > two-fold in all samples of the respec-
tive biological replicate group) and non-changing genes
(normalised expression levels from 0,667 to 1,334 in at
least 4 of 4 conditions) were subtracted. The remaining
data set was tested for differentially expressed genes using
ANOVA (GeneSpring Expression Analysis 7.3.1 tool, Agi-
lent Technologies). A p-value of p < 0.05 (Welch t-test)
was considered significant. Expression differences of at
least two-fold were considered relevant. Not fully anno-
tated probes, i.e. probes that did not correspond to a
NCBI RefSeq, EST or RIKEN cDNA, were excluded. Func-
tional annotation and clustering of the differentially regu-
lated genes was performed using the Gene Functional
Classification tool of the database for annotation, visualisa-
tion and integrated discovery (DAVID; http://david.abcc.
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ncifcrf.gov/[68,69]). The array data have been deposited in
the Gene Expression Omnibus database, http://www.ncbi.
nlm.nih.gov/geo (GEO accession no. GSE22691).
Additional material
Additional file 1: Oct-6 protein is expressed in pMEFs in response
to IFNb treatment. Bandshift assays including supershifts with a-Oct-1,
a-Oct-2 and a-Oct-6 antibodies and Oct-6-/- MEFs as controls.
Additional file 2: Expression of Oct-6 during MCMV infection is
largely dependent on type I IFN and Jak/Stat signalling. Bandshift
assays of whole cell extracts from WT, IFNb-/-, Ifnar1-/-, Tyk2-/-, and Stat1-/-
macrophages infected with MCMV.
Additional file 3: Oct-6 DNA-binding activity in response to IFNb or
poly(I:C) treatment in foetal liver- and bone marrow-derived
macrophages.
Additional file 4: Overexpression of Oct-6 in pMEFs enhances the
expression of IFNb and IFNa mRNAs, but does not influence the
expression of Egr2 and Pmp22 mRNAs.
Additional file 5: Absence of Oct-6 does not influence the
expression patterns of panIFNa, IFNb, Egr2 and Pmp22 mRNAs
upon DNA transfection in MEFs. Comparison of transfected WT and
Oct6-deficient foetal liver-derived macrophages.
Additional file 6: Absence of Oct-6 in macrophages has no impact
on MCMV replication at a MOI of 0.1. Comparison of MCMV
replication in WT and Oct-6-deficient foetal liver-derived macrophages at
a lower MOI.
Additional file 7: Differentially expressed genes as determined by
microarray analysis that could be functionally annotated (96 out of
200; WT vs. Oct-6-/-, at least 2-fold difference, p <0.05).
Additional file 8: Complete list of differentially expressed genes
(WT vs. Oct-6-/-, at least 2-fold difference, p <0.05).
Additional file 9: 3A (sheet 1): Gene Ontology categories up-
regulated by poly(I:C) treatment in WT cells (p <0.05); 3B (sheet 2):
Gene Ontology categories down-regulated by poly(I:C) treatment in
WT cells (p <0.05).
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